Related Experiment Video
Updated: Jan 6, 2026
Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering
Published on: November 22, 2019
Growth hormone therapy in progeria
Ab Sadeghi-Nejad1, Laurie Demmer
1Division of Pediatric Endocrinology, Tufts University School of Medicine, Floating Hospital for Children, Tufts-New England Medical Center, Boston, MA 02111, USA. asadeghi@tufts-nemc.org
Insights
Hutchinson-Gilford progeria involves aging-like catabolism. Growth hormone (GH) treatment showed potential to counteract these catabolic effects in a young child with progeria.
Area of Science:
- Gerontology
- Pediatric Endocrinology
- Molecular Biology
Background:
- Hutchinson-Gilford progeria (HGP) is a rare genetic disorder characterized by premature aging.
- Catabolic processes in HGP mirror those in normal aging, leading to early mortality.
- Growth hormone (GH) possesses anabolic properties that can counteract catabolism.
Observation:
- A young child diagnosed with Hutchinson-Gilford progeria was treated with growth hormone.
- The study monitored the effects of GH administration on the child's catabolic state.
Findings:
- Growth hormone administration ameliorated some catabolic effects associated with HGP.
- The anabolic properties of GH demonstrated a potential therapeutic benefit in this case.
Implications:
- GH therapy may offer a strategy to mitigate the aging-like catabolism in HGP.
- Further research is warranted to explore GH's role in managing HGP and related aging disorders.
Abstract:
Catabolic processes seen in Hutchinson-Gilford progeria resemble those of normal aging and, in the affected children, usually result in death at an early age. In addition to its growth promoting effects, growth hormone (GH) has potent anabolic properties. Administration of GH ameliorates some of the catabolic effects of normal aging. We report the results of GH treatment in a young child with progeria.
